With CoapTech, Steven Tropello and Howard Carolan are working on new technology for replacing patients’ feeding tubes.
The approach, called Percutaneous Ultrasound Gastrostomy, or PUG, utilizes a device with magnets that doctors can use to guide a feeding tube into place. It also features an ultrasound that allows doctors to see what is happening inside the body as the tube as it goes to the stomach, and identify the safest site for the tube to be placed.
It was a huge year for Marriott International Inc., as it closed on its acquisition of Starwood Hotels & Resorts Worldwide.
And that meant it was also a huge year for Marriott CEO Arne Sorenson.
AbbVie (ABBV), a global biopharmaceutical company, and the Johns Hopkins University School of Medicine today announced that they signed a five-year collaboration agreement with the goal of advancing medical oncology research and discovery at both organizations.
Designed to build strong collaboration between AbbVie and Johns Hopkins Medicine researchers, the agreement will focus on several areas of oncology research, which could include lung, colorectal, breast, prostate and hematological cancer.
Funding and Research OpportunitiesThe following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
- Notice of Extension of the Response Date for NOT-OD-17-015 “Strategies for
- NIH Data Management, Sharing, and Citation”
- (NOT-OD-17-025) National Institutes of Health
- Revision: Participation of the National Institute of Dental and Craniofacial
- Research (NIDCR) in PAR-15-282 “Multidisciplinary Studies of HIV/AIDS and
- Aging (R21)”
- (NOT-DE-17-005)
- National Institute of Dental and Craniofacial Research
- Request for Information (RFI): Biological Mechanisms/Pathways of the Combined
- Effects of Chemical and Non-chemical Stressors Associated with Atherosclerosis
- (NOT-ES-17-003)
- National Institute of Environmental Health Sciences
- National Heart, Lung, and Blood Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Catalyzing
- Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans
- (U34)
- (NOT-HL-16-473)
- National Heart, Lung, and Blood Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Catalyzing
- Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans
- (X01)
- (NOT-HL-16-474)
- National Heart, Lung, and Blood Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI Early
- Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33)
- (NOT-HL-16-475)
- National Heart, Lung, and Blood Institute
- Notice of Intent to Publish a Funding Opportunity Announcement for Sex
- Hormone Induced Thromboembolism in Pre-Menopausal Women (R61/R33)
- (NOT-HL-16-477)
- National Heart, Lung, and Blood Institute
- Soon to be Issued Funding Opportunity for All of Us Research Program
- Community Engagement (OT2)
- (NOT-PM-17-001)
- National Institutes of Health
- Notice of Change to Background for RFA-RM-16-024 “Knowledge Management
- Center for Illuminating the Druggable Genome (U24)”
- (NOT-RM-17-002)
- NIH Roadmap Initiatives
- Notice of Change to Background for RFA-RM-16-025 “Resource Dissemination and Outreach Center for Illuminating the Druggable Genome (U24)”
- Notice of Change to Background for RFA-RM-16-026 “Data and Resource
- Generation Centers for Illuminating the Druggable Genome (U24)”
- (NOT-RM-17-004)
- NIH Roadmap Initiatives
Honoring those who see past the present to define the future
The future is not granted. It is born from the imagination of entrepreneurs. If you are a successful entrepreneur or have been inspired by an enterprising trailblazer, we’d like you to submit a nomination to the EY Entrepreneur Of The Year® 2017 program.
About the Entrepreneur Of The Year Program
Since 1986, EY has celebrated the accomplishments of thousands of entrepreneurs who have shaped the way we live, work and play. We recognize and honor these inspiring individuals through the Entrepreneur Of The Year.
Over three decades, the program has grown to span more than 145 cities, in more than 60 countries, and now boasts a roster of nearly 10,000 visionary trailblazers here in the US.
Wednesday, December 09, 2015
Dear Friends and Colleagues, This next DC SoPE event is a must for every healthcare/life science entrepreneur, innovator, and potential investor! Our panel will answer questions about terms sheets from the audience…from the most basic to the most erudite. Please join us and pass the information along to your constituents and stakeholders. Thanks for your support in nurturing the Healthcare/Life science ecosystem in the DC region.
Inova announced today that Milton L. Brown, MD, PhD, has joined Inova where he will serve as director of the new Inova Center for Drug Discovery and Development and as deputy director for Drug Discovery for the Inova Schar Cancer Institute (ISCI). Dr. Brown is a physician scientist who has expertise in the design, synthesis, and evaluation of new drugs and is one of only a handful of physician scientists in the United States who hold a PhD in synthetic chemistry and an MD. He comes to Inova from Georgetown University Medical Center where he was founding director of the Drug Discovery Program (DDP).
Wednesday, December 14, 7 – 11 amFalls Church Marriott Fairview Park
Super Early Bird expires November 3rd for our CONNECTpreneur Winter Forum, headlined by Revolution Chairman & CEO, STEVE CASE, former AOL Time Warner Chair and New York Times bestselling author of The Third Wave.
The Big Idea CONNECTpreneur FORUM has been called “The Best Networking Event in DC.” DCInno calls CONNECTpreneur a “NETWORKING JACKPOT” of the DC Region’s TOP Entrepreneurs, Business Leaders, CXOs, Angels, and VCs.
BioBuzz Workforce Foundation, Inc., a social community organization whose mission is to build a more connected bioscience industry in the region, today announced a partnership with The City of Frederick Department of Economic Development and the Frederick County Chapter of BioBeers Meetup group. This new collaboration will give Frederick companies access to BioBuzz’s BioHive Platform and showcase them as important components within the ecosystem.
The Trump administration will have an opportunity to reevaluate policies that affect innovation and technological development. How can federal policies promote broadband buildout, spur investment in intelligent infrastructure, encourage research and development, and advance a host of other actions that have the potential to improve productivity and the U.S. economy? Join ITIF and the Technology Policy Institute to discuss how the Trump administration can accelerate the pace of innovation in the U.S. economy.
It’s hard to get excited about a biotech shared-space in 2016.
Four years ago, it was an exciting and rapidly diversifying field. Now incubators are par for the course, with most Big Pharma and many institutions operating their own version.
Mass Innovation Labs was late to the game, opening in May 2015. But it is clearly doing something different.
A defining moment in modern biology occurred on July 24, 1978, when biotechnology pioneer Robert Swanson, who had recently co-founded Genentech, brought two young scientists to dinner with Thomas Perkins, the legendary venture capitalist. As they stood outside Perkins’s magnificent mansion in Marin County, with its swimming pool and garden and a view of the Golden Gate Bridge, Swanson turned to his two young colleagues and said, “This is what we’re all working for.”
Lingering for more than two years, the revamped 21st Century Cures bill, unveiled in late November, has now been approved by the House and Senate and President Barack Obama has said he will sign it.
The 996-page bill includes major tweaks to the way in which the US Food and Drug Administration (FDA) regulates drugs, devices and biologics, while providing the agency with $500 million over 10 years to implement provisions that seek to move such products to patients more quickly, while maintaining the same standard for safety and effectiveness that the agency has adhered to in the past.
Entrepreneurs can’t sit still for long.
Four months after announcing his departure from Google Ventures (now GV), which he cofounded and led, Bill Maris is reportedly raising a fresh $230 million VC fund that will focus on healthcare investments.
President-elect Trump didn’t talk a lot about the Food and Drug Administration while he was on the campaign trail, but judging from what he did say, he will want the FDA to approve new drugs and products much faster.
The one thing venture capitalists and the medtech industry don’t want you to know is that innovation can sometimes be used as a manipulation to evade the law.
The industry can sometimes, even knowingly, be deceptive in three very specific ways. These are: lie to government agencies, underreport adverse events, blame the employees and consumer (victims). My goal as a federal whistleblower is to explain how these at times carefully crafted lies impacts each of you.
The rise of diabetes is causing avoidable deaths and imposing substantial costs on ailing healthcare systems. Alarmed, lawmakers are attempting to improve prevention and get the emerging pandemic under control.
Diabetes is a growing healthcare challenge and one of the four priority noncommunicable diseases (NCDs), also known as chronic diseases, targeted for urgent action by world leaders.
Walking around San Francisco’s Union Square during biotech conference season in January—during this time of industry prosperity—you might expect it to be crawling with brainy young people. You might expect hot startups to come from students and postdocs, like in the tech industry, with VCs scrambling to get in on the ground floor.
Despite a recent tapering of year-on-year growth, the global market for prescription drugs is forecast to reach $1.5 trillion per year by 2021, a 33 percent increase from 2016.
That’s according to a new report by the QuintilesIMS Institute, the research arm of the healthcare informatics company QuintilesIMS.
Ascension Ventures (AV) has finalized its latest strategic venture capital fund at $255 million. This fourth fund for AV, CHV IV, L.P., brings the firm’s total assets under management to more than $800 million. The new fund is backed by 13 health system partners, which enable AV to continue to add value to its portfolio companies while simultaneously delivering financial and strategic returns to the partners.
